

CSD/BSE&NSE/RPT/2021-22 May 20, 2021

To

The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239 Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

......

Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions on a consolidated basis and balances for the year ended March 31st, 2021.

We request you to take this document on your record.

Thanking you,

Yours faithfully,

For Suven Life Sciences Limited

Shrenik Soni

Company Secretary

Encl.: as above



Disclosure of related party transactions on a consolidated basis

List of related parties on consolidated basis as per Reg. 23(9)

(a) Holding Company

Jasti Property and Equity Holdings Private Limited (Holding in its capacity as sole trustee of Jasti Family Trust)

(b) Subsidiary

Suven Neurosciences Inc. (USA)

(c) Key Management personnel (KMP)

Mr. Venkateswarlu Jasti Mrs. Sudharani Jasti Prof. Dr. Seyed E. Hasnain Mr. M. Gopalakrishna Mr. Santanu Mukherjee Mrs. J.A.S. Padmaja Chairman & CEO
Whole-time Director
Non-executive Director
Independent Director
Independent Director
Independent Director

(d) Entities with common control

Suven Pharmaceuticals Limited Suven Pharma Inc.

Suven Life Sciences Limited



Transactions during the year ended 31st March, 2021 with related parties

Rupees in lakhs

	Rupees III lukiis
Particulars	For the year ended 31 st March 2021
Parent entities	
Jasti Property and Equity Holdings Private Limited (Holding in its capacity as sole trustee of Jasti Family Trust)	60.00%
Subsidiaries	
Balance outstanding	29,502.55
Key Management Personnel compensation	
Short term employee benefits	215.32
Balance outstanding	Nil
Entity with common control	
Rent Expenses	104.87
Interest Income on Loan given	697.91
Intercorporate Loan to Suven Pharmaceuticals Ltd.	0.00
i. Loan Given	0.00 9180.43
ii. Receipts during the year towards Loan Given	4144.82
iii. Outstanding Loan at the year endService Income	7144.02
Income from services rendered	248.46

Suven Life Sciences Limited